Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radium-223 + sipuleucel-T
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Radium-223 + sipuleucel-T is a combination therapy being investigated for the treatment of bone-metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (Xofigo) is an alpha-emitting radiopharmaceutical that acts as a calcium mimetic, selectively targeting areas of high bone turnover associated with metastases to deliver high-energy, short-range alpha radiation that induces DNA double-strand breaks. Sipuleucel-T (Provenge) is an autologous cellular immunotherapy composed of peripheral blood mononuclear cells, including antigen-presenting cells, that have been activated ex vivo with a recombinant fusion protein (PA2024) containing prostatic acid phosphatase (PAP). The combination, evaluated in a Phase 2 trial (NCT02463799) led by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, aims to enhance the anti-tumor immune response by combining localized radiation-induced cell death with systemic immunotherapy.
- Brand names
- XofigoProvenge
- Other names
- radium-223 dichlorideradium223 dichlorideradium 223 dichlorideAPC8015APC-8015APC 8015
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on radium-223 + sipuleucel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radium-223 + sipuleucel-T.